These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 2609913

  • 1. Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor.
    Eggermont AM, Sugarbaker PH.
    Acta Med Austriaca; 1989; 16(3-4):47-50. PubMed ID: 2609913
    [Abstract] [Full Text] [Related]

  • 2. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM, Sugarbaker PH.
    Cancer Detect Prev; 1990 Aug; 14(4):483-90. PubMed ID: 2224911
    [Abstract] [Full Text] [Related]

  • 4. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 5. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E, Ben-Aziz R, Shiloni E.
    Isr J Med Sci; 1988 Dec; 24(9-10):494-504. PubMed ID: 3264551
    [Abstract] [Full Text] [Related]

  • 6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA, Mulé JJ.
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 12. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S, Naito K, Kahan BD, Pellis NR.
    Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
    [Abstract] [Full Text] [Related]

  • 13. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
    Papa MZ, Vetto JT, Ettinghausen SE, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Nov; 46(11):5618-23. PubMed ID: 3489525
    [Abstract] [Full Text] [Related]

  • 14. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice.
    Agah R, Malloy B, Kerner M, Girgis E, Bean P, Twomey P, Mazumder A.
    Cancer Res; 1989 Nov 01; 49(21):5959-63. PubMed ID: 2790810
    [Abstract] [Full Text] [Related]

  • 15. [Interleukin 2: immunologic background and clinical use in tumor therapy].
    Dummer R, Welters H, Keilholz U, Tilgen W, Burg G.
    Hautarzt; 1990 Feb 01; 41(2):53-5. PubMed ID: 2180854
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2.
    Potapnev MP, Istomin YP, Ismail-zade RS, Zhavrid EA.
    Eksp Onkol; 2004 Mar 01; 26(1):67-70. PubMed ID: 15112583
    [Abstract] [Full Text] [Related]

  • 17. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 01; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 18. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K, O'Donnell RW, Cockett AT.
    J Biol Response Mod; 1988 Feb 01; 7(1):43-53. PubMed ID: 3259620
    [Abstract] [Full Text] [Related]

  • 19. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
    Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):122-9. PubMed ID: 3257159
    [Abstract] [Full Text] [Related]

  • 20. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.